Epidemiology Of Pancreatic Cancer Research Articles

Epidemiology of pancreatic cancer

At present, pancreatic cancer morbidity continues to grow at an accelerated rate worldwide. At the same time the five-year survival rate of patients with pancreatic cancer remains low, occupying a significant position in the mortality structure. This is mainly due to late diagnosis, as well as to the increasing proportion of the elderly population. Factors influencing the prognosis include age, sex, blood group, family history and genetic predisposition, diabetes, smoking, alcohol, chronic pancreatitis, and obesity. Objective: to present up-to-date data on pancreatic cancer epidemiology in the world, Russian Federation and Omsk region. Materials and methods: the article analyzes the data of morbidity, mortality and five-year survival rate of patients with pancreatic cancer for the years 2020-2021. Results: the growth of morbidity and persistent low survival rates emphasize the necessity of determining methods of screening patients with high risk of pancreatic cancer, developing methods of early detection and improving both surgical and drug treatment of these patients, as well as prophylaxis.

Overview of Pancreatic Cancer Epidemiology in Europe and Recommendations for Screening in High-Risk Populations.

Pancreatic cancer is the seventh most common cause of death in the group of oncological diseases. Due to the asymptomatic course, early diagnosis is difficult. Currently, early detection methods are only used in high-risk groups. A literature review based on the available results of observational studies on patients with pancreatic cancer and people from high-risk groups was used to summarize the knowledge on risk factors. The GLOBOCAN 2020 data were used to assess the epidemiological situation in Europe. A summary of screening recommendations was prepared based on the available documents from medical organizations and associations. Pancreatic cancer risk factors are divided into two main groups: non-modifiable factors, e.g., hereditary factors and age, which increase the risk of developing this disease, and modifiable factors-BMI, smoking, and alcohol consumption. Hereditary factors account for 10% of pancreatic cancer cases. The highly specialized methods of early detection, (MRI, CT, or EUS) are used for screening high-risk populations. Of all the imaging methods, EUS is considered the most sensitive for pancreatic cancer and allows an accurate assessment of the size of even small lesions (<30 mm) and the extent of tumour infiltration into blood vessels. The available studies vary on the level of sensitivity and specificity of these methods for the diagnosis of pancreatic cancer. EUS, MRI, and CT are also expensive procedures and in some patients can be invasive, which is one of the arguments against the introduction of population screening programs based on imaging methods. Therefore, it is important to look for viable solutions that would improve early detection. This is important from the point of view of healthcare systems in Europe, where almost 29% of all global pancreatic cancer cases are reported.

Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention

Pancreatic cancer usually results in poor survival with limited options for treatment, as most affected individuals present with advanced disease. Early detection of preinvasive pancreatic neoplasia and identifying molecular therapeutic targets provide opportunities for extending survival. Although screening for pancreatic cancer is currently not recommended for the general population, emerging evidence indicates that pancreatic surveillance can improve outcomes for individuals in certain high-risk groups. Changes in the epidemiology of pancreatic cancer, experience from pancreatic surveillance, and discovery of novel biomarkers provide a roadmap for new strategies for pancreatic cancer risk assessment, early detection, and prevention.

MAIN EPIDEMIOLOGICAL ASPECTS OF PANCREATIC CANCER IN KAZAKHSTAN

According to GLOBOCAN (2020), pancreatic cancer (PC) is in 12th place among oncopathology in terms of incidence - 4.9 cases per 100,000 population. Most cases of pancreatic cancer are registered in China, the USA, Japan, and Germany. In the structure of mortality among oncological diseases, pancreatic cancer occupies 9th place - 4.5 cases per 100 thousand of the population. According to epidemiological studies, by 2040, a 79.9% increase in mortality from pancreatic cancer is predicted. According to statistics, in the United States, there is an increase in the incidence of cancer in the distal pancreas. In addition, early stages of pancreatic cancer were diagnosed more often and less often - the 4th. One of the trends in the epidemiology of pancreatic cancer is an increase in the incidence of this pathology among young people. Factors contributing to the development of pancreatic cancer in people under 50 years of age are genetic mutations, smoking, and obesity. A retrospective statistical analysis of the epidemiological state of pancreatic cancer in Kazakhstan over 3 years was carried out (standardized WHO World indicators per 100,000 population and intensive indicators of morbidity, mortality, distribution by stage, age, and sex), and regional features of pancreatic cancer were studied.

Descriptive, analytical and molecular epidemiology of pancreatic cancer

The purpose of the study was to present current data on the role of lifestyle and heredity factors in the etiology of pancreatic cancer (PC). Material and Methods. A systemic literature search was conducted using Medline and Elibrary databases. Results. Pancreatic cancer is the 9th leading cause of cancer-related deaths worldwide. PC has an extremely poor prognosis. The 5-year survival rate of patients with PC does not exceed 9 %. The highest incidence and mortality rates from PC are found in Eastern Europe, including Russia. The incidence of PC in 2019 was 9.3 per 100,000 males and 5.7 per 100,000 females. In Russia, PC incidence and mortality rates in both males and females show a steady increase. Risk factors associated with PC include smoking, heavy alcohol drinking, overweight and obesity, diabetes and chronic pancreatitis. The microbiome of the oral cavity and colon infuence the risk of PС. Approximately 10 % of PC is estimated to have familial inheritance. The risk of PC in patients with inherited syndromes ranges from 2 (hereditary breast and ovarian cancer syndrome) to 132 (Peutz-Jeghers syndrome). Regions of the genome containing variants of single nucleotide polymorphism (SNPs), which are more common in patients with PC than in healthy people, were identifed. The most common somatic mutations include mutations in the driver genes of prostate cancer, which include the KRAS oncogene and tumor suppressor genes TP53, CDKN2A, and SMAD4.The less common mutations of genes include AIB1/NCOA, ERBB2/HER2/EGFR2, AKT2, BRAF, CCND1, RB1, etc. They are identifed as “passenger” mutations although the combined effect of polymorphism of these genes can be signifcant and comparable to the infuence of the driver gene. Conclusion. A signifcant disadvantage of our understanding of the process of carcinogenesis is the lack of information about carcinogenic factors that cause specifc mutations, i.e. the formation of mutational signatures. To solve this problem, in 2017, the international scientifc project GRAND CHALLENGE “Mutograph” was launched. The scientists of the Department of Cancer Epidemiology of N. N. Blokhin National Medical Research Center of Oncology are members of the international team working on this project.

Multidisciplinary Management of Pancreatic Cancer.

At JADPRO Live Virtual 2021, presenters reviewed the epidemiology of pancreatic cancer, treatment options for patients with different stages of pancreatic cancer, and the most common symptoms and complications related to pancreatic cancer and their management in a collaborative practice model.

Anaesthesia for Pancreatic Surgery.

This article provides a broad perspective on the salient perioperative issues encountered when caring for patients undergoing pancreatic surgery in the setting of pancreatic cancer. It describes the epidemiology of pancreatic cancer, the indications for and evolution of pancreatic resection surgery, the challenges faced perioperatively including patient selection, optimization, anesthetic considerations, postoperative analgesia, fluid management, and nutrition and discusses some of the common complications and their management. It finishes by outlining the future directions for research and development required to continue improving outcomes for these patients.

Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis.

Pancreatic cancer is a malignancy with poor prognosis and high mortality. The recent increase in pancreatic cancer incidence and mortality has resulted in an increased number of studies on its epidemiology. This comprehensive and systematic literature review summarizes the advances in the epidemiology of pancreatic cancer, including its epidemiological trends, risk factors, risk prediction models, screening modalities, and prognosis. The risk factors for pancreatic cancers can be categorized as those related to individual characteristics, lifestyle and environment, and disease status. Several prediction models for pancreatic cancer have been developed in populations with new-onset diabetes or a family history of pancreatic cancer; however, these models require further validation. Despite recent progress in pancreatic cancer screening, the quantity and quality of related studies are also unsatisfactory, especially with respect to the identification of high-risk populations and development of effective screening modality. Apart from the populations with familial genetic risk and those at a high risk of sporadic pancreatic cancer, risk factors such as new-onset diabetes may be a new direction for timely intervention. We hope this work will provide new ideas for further prevention and treatment of pancreatic cancer.

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer.

Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches.

An epidemiological review of pancreatic cancer with special reference to India

Pancreatic cancer (PC) is a rare cancer site, ranked 14th in incidence and 7th in mortality in the world. In India, pancreas ranks 24th with 10860 new cases (1.03%) and 18th in mortality. Although PC is a rare site, it is a leading mortality site across the globe and very little data are available about the epidemiology of PC. It is hypothesized that due to the changing lifestyle globally and, in India, the rates of PC will increase in the near future. Thus, this study aims to report PC incidence, mortality, globally but with more emphasis with respect to Indian population and associated factors for PC, since changing lifestyle has had an impact on the occurrence of the disease over the years. Incidence and mortality rates are obtained from GLOBOCAN-2018 and cancer incidence in five continents (CI5- XI), and Indian Council of Medical Research publication on Indian cancer registry database. Incidence is higher in elderly population (more than 50% in 65–75 years). The incidence is highest among Northeastern Indian regions. Risk factors include smoking, high alcohol consumption, non-vegetarian diets (modifiable) and age, race, and the genetic predispositions (non-modifiable) risk factors. No case–control studies on risk factors are reported yet based on the Indian population. Increase of PC numbers is a cause for concern, since it mostly manifests on the lifestyle factors, which is rapidly changing in India, like in other parts of the globe. This study will be useful in giving some leads on the PC’s possible causes and thereby help in formulating strategies for reducing the burden of this disease.

Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors.

Pancreatic cancer is a leading cause of cancer death worldwide and its global burden has more than doubled over the past 25 years. The highest incidence regions for pancreatic cancer include North America, Europe and Australia, and although much of this increase is due to ageing worldwide populations, there are key modifiable risk factors for pancreatic cancer such as cigarette smoking, obesity, diabetes and alcohol intake. The prevalence of these risk factors is increasing in many global regions, resulting in increasing age-adjusted incidence rates for pancreatic cancer, but the relative contribution from these risk factors varies globally due to variation in the underlying prevalence and prevention strategies. Inherited genetic factors, although not directly modifiable, are an important component of pancreatic cancer risk, and include pathogenic variants in hereditary cancer genes, genes associated with hereditary pancreatitis, as well as common variants identified in genome-wide association studies. Identification of the genetic changes that underlie pancreatic cancer not only provides insight into the aetiology of this cancer but also provides an opportunity to guide early detection strategies. The goal of this Review is to provide an up-to-date overview of the established modifiable and inherited risk factors for pancreatic cancer.

COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London

ObjectiveTo explore risk factors associated with COVID-19 susceptibility and survival in patients with pre-existing hepato–pancreato–biliary (HPB) conditions.DesignCross-sectional study.SettingEast London Pancreatic Cancer Epidemiology (EL-PaC-Epidem) Study at Barts Health National Health Service...

Epidemiology of Pancreatic Cancer in Saudi Arabia: A Retrospective Analysis of Pancreatic Cancer Diagnosed in Saudi Arabia Between 2004 and 2015.

PurposeOver the last decades, the incidence of pancreatic cancer has increased, particularly in countries with a higher socioeconomic status. The present work aimed to provide detailed epidemiological data on the incidence of pancreatic cancer in Saudi Arabia.Patients and MethodsIn this retrospective descriptive study, the epidemiological data on pancreatic cancer cases diagnosed in 13 administrative regions of Saudi Arabia between January 2004 and December 2015 were extracted from the Saudi Cancer Registry. The frequency, the crude incidence rate (CIR), and the age-standardized incidence rate (ASIR), stratified by geographical region, gender, and the year of diagnosis, were analyzed.ResultsFrom January 2004 to December 2015, a total of 2338 cases of pancreatic cancer were registered, including 1443 males and 895 females. The overall CIR was 1.28/100,000 among males and 0.80/100,000 in females, with an overall ASIR of 2.26 and 1.41/100,000 for males and females, respectively. Higher ASIR and CIR were observed among males than females (ratio 1.6). In both genders, the ASIR of pancreatic cancer increased with increasing age, with the highest incidence in patients aged 70 years or more. The ASIR in the Eastern Region (3.2/100,000) and the regions of Riyadh (3.0/100,000) and Tabuk (2.6/100,000) proved to be significantly higher than in the other regions of the country. Among women, the ASIR was significantly higher in Riyadh (2.3/100,000), the northern region (2.2/100,000), and Tabuk (2.0/100,000).ConclusionThis study revealed a slight increase of the CIR and ASIR of pancreatic cancer among males and females of the Saudi population. Eastern region, Riyadh, and Tabuk had the highest overall ASIRs of pancreatic cancer among males, Riyadh, Northern region, and Tabuk among Saudi females. The area least affected by pancreatic cancer was observed in Jazan among male and female Saudis. The rates of pancreatic cancer in Saudi Arabia were significantly higher among males compared with female Saudis. Further analytical studies are needed to identify the potential risk factors for pancreatic cancer among the Saudi population.

The Epidemiology of Pancreatic Cancer and the Association With Acetylsalicylic Acid in the United States: A Population-Based Study.

Pancreatic cancer (PaC) is the third leading cause of cancer-related death in the United States. Multiple studies have investigated the epidemiology and the association between PaC and acetylsalicylic acid (ASA) use, revealing mixed results. Using a large database, we sought to investigate the epidemiology of PaC. Using a commercial database (Explorys Inc, Cleveland, Ohio), which includes electronic health record data from 26 major integrated US health care systems, all patients 18 years and older diagnosed with PaC for 5 years were identified based on Systematized Nomenclature Of Medicine-Clinical Terms. We determined the prevalence of PaC and the potential associated factors using univariable and multivariable analysis. Of the 32,970,850 individuals, we identified 30,250 individuals with PaC with an overall prevalence of 0.08%. Individuals with PaC were more likely to be males, seniors (age, >65 years), and White, compared with patients without PaC. In subgroup analysis of chronic pancreatitis, individuals on ASA, individuals >65 years, White, and White males were less likely to have PaC, and non-White females were more likely to have PaC. This is the largest population-based study evaluating the epidemiology of PaC. We observed a protective association of ASA on a subgroup of patients with PaC and chronic pancreatitis.

P-277 Epidemiology of pancreatic cancer: Experience of the medical oncology department of CHU Hassan II Fez

Pancreatic cancer is a malignant tumor developed at the expense of pancreatic tissue, represents 2% of all cancers, and is the 4th leading cause of death from cancer worldwide. Its life expectancy at 5 years is 5%. The prognosis for this cancer is dire. Its incidence and mortality rate are similar.

The global burden of pancreatic cancer.

IntroductionWe provide here an overview on current worldwide epidemiology of pancreatic malignancies, obtained from Global Health Data Exchange (GHDx) and World Health Organization (WHO) repositories.Material and methodsElectronic searches for collecting information on pancreatic cancer epidemiology were performed in official repositories of GHDx and WHO, and retrieved data were then analyzed.ResultsOverall, 447 665 new cases of pancreatic cancer were recorded around the world in 2017 (58.6 per million), with global prevalence of 49.8 per million and 441 083 deaths (57.7 per million). Incidence, prevalence and mortality increased by 55%, 63% and 53% during the last 25 years. Pancreatic cancer accounts for 1.8% of all cancers, causing 3.9% of all cancer disability- adjusted life years (DALYs) and 4.6% of all cancer deaths. No sex differences can be observed for incidence, prevalence and mortality, whilst DALYs are marginally higher in men. Incidence, prevalence and mortality follow a similar age-related trend, with gradual escalation after 30 years of age, reaching the highest burden after 80 years of age. The DALYs peak between 55 and 74 years, and then decline. The epidemiologic burden is positively associated with socio-demographic status. The largest burden of pancreatic cancers is observed in the East and Asia Pacific region, whilst the lowest is found in the Middle East and North Africa. Pancreatic cancer deaths are expected to increase by ~1.97-fold by the year 2060.ConclusionsAlthough pancreatic cancer remains relatively infrequent, its clinical, societal and economic burden is noteworthy. Future projections suggest that its burden may double during the next 40 years.

Current epidemiology of pancreatic cancer: Challenges and opportunities.

Pancreatic cancer (PC) is an increasingly common disease worldwide. Having a better understanding of worldwide and regional epidemiologic features and risk factors of PC is essential to identify new approaches for prevention, early diagnosis, surveillance, and treatment. In this article, we review the epidemiologic features and risk factors for PC and discuss opportunities and challenges of PC future treatment.

5 The Prevalence and Epidemiology of Pancreatic Cancer in the USA: A Population-Based Study

INTRODUCTION: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. Multiple studies have reported the epidemiology of this disease with conflicting results and limited sample size. Our aim is to further investigate the epidemiology of pancreatic cancer using a large database. METHODS: We used a commercial database (Explorys Inc, Cleveland, OH) which includes electronic health record data from 26 major integrated US healthcare systems. We identified all patients aged 18 and older who were diagnosed with pancreatic cancer, over the last 5 years based on Systematized Nomenclature Of Medicine – Clinical Terms (SNOMED-CT) and evaluated the prevalence of pancreatic cancer among all the patients in this database. We also performed univariate analysis to describe age-, race-, and gender-based distributions and to identify potential risk factors. RESULTS: Of the 36,728,450 individuals in the database, we identified 41,610 individuals with pancreatic cancer with an overall prevalence of 0.11%. Individuals with pancreatic cancer were more likely to be males, senior adults (age &gt;65), Caucasians, (P &lt; 0.0001 to all) compared to patients without pancreatic cancer. Similarly, patients with pancreatic cancer were more likely to have cystic fibrosis, viral hepatitis B and C, acute and chronic pancreatitis, diabetes mellitus type 1 and 2, (P &lt; 0.0001 to all). Additionally, patients with pancreatic cancer were more likely to be smokers, drink alcohol, and take non-steroidal anti-inflammatory drugs (NSAIDs), (P &lt; 0.0001 to all). Table 1 represents the odds ratio (OR) for all factors. CONCLUSION: This is one of the largest epidemiological studies investigating the prevalence and epidemiology of pancreatic cancer. Estimated prevalence rate of pancreatic cancer was 0.11%. Patients with pancreatic cancer were more likely to be males, senior adults (age &gt;65), Caucasians, smokers, and take NSAIDs. They were also more likely to have Diabetes, Chronic pancreatitis, Hepatitis B, and Hepatitis C. Further studies are needed to confirm these findings.

Spatial Epidemiology of Pancreatic Cancer in South Dakota.

Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States. Descriptive epidemiology of pancreatic cancer in South Dakota has not been studied before. All cases of pancreatic cancer reported to the SD Cancer Registry between January 2005 and December 2014 were included in the study. Variables collected included demographics, geographical location including county of residence and zip codes, date of diagnosis, date of last contact or follow-up, size and location of the tumor, grade of the tumor, diagnostic modality as well as therapeutic interventions. Log rank test was used to compare survival curves. Kaplan-Meier product limit estimates were provided. Data was analyzed using SAS 9.1.4 software. One thousand sixty-four cases of pancreatic cancer were reported. Median age was 73years. Cumulative age-adjusted incidence rate for pancreatic cancer for 2005-2014 was 11.1. Cumulative age-adjusted mortality rate for pancreatic cancer for 2005-2014 was 10.2. Almost half of these patients had distant metastasis at the time of presentation (n = 536; 50.4%). Overall, median survival was 5months. Median survival for patients under the age of 60years was 9.5months as opposed to median survival for patients 60years or older which was 3.9months. Median survival of patients with well-differentiated, moderately differentiated, and poorly differentiated tumors, was 20.8months, 8.2months and 6.3months respectively (p value = 0.0017). Incidence of pancreatic cancer in South Dakota is similar to the national trends in the United States. Age at presentation, location of tumor in pancreas, and biological behavior of tumor were all predictors of survival in patients with pancreatic cancer.

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors, Helicobacter pylori infection, non-O blood group and chronic pancreatitis. In general population, screening of large groups is not considered useful to detect the disease at its early stage, although newer techniques and the screening of tightly targeted groups (especially of those with family history), are being evaluated. Primary prevention is considered of utmost importance. Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease.